

Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron (Results of Phase III ACHIEVE-1 for Type 2 Diabetes Published in The New England Journal of Medicine)

TOKYO, June 23, 2025 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that [Eli Lilly and Company](#) (hereafter “Eli Lilly”, NYSE: LLY) issued a news release on June 21, 2025 (local time), that the detailed results of the positive Phase 3 results from ACHIEVE-1 study, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone, were presented at the American Diabetes Association (ADA) 85th Scientific Sessions 2025 and simultaneously published in [The New England Journal of Medicine](#).

Please refer to the Latest News via the following link, for details of Eli Lilly's news release: Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
<https://investor.lilly.com/>

###